Myeloablative vs. Reduced Intensity Conditioning for Hematopoietic Cell Transplantation in Acute Myeloid Leukemia and Myelodysplastic Syndromes —Long Term Follow up of BMT CTN 0901 Clinical Trial

Hematopoietic cell transplantation (HCT) is the only curative option for patients with myelodysplastic syndrome (MDS) and is frequently used as the preferred consolidative strategy in patients with intermediate and adverse risk acute myeloid leukemia (AML). While myeloablative conditioning (MAC) prior to HCT may be curative there is considerable toxicity and treatment-related mortality (TRM). The understanding that the curative potential of HCT is in part due to the graft vs. leukemia effect (GVL) mediated by donor cells led to the development of reduced-intensity conditioning (RIC) regimens with reduced TRM.

Source: Biology of Blood and Marrow Transplantation - February 26, 2021 Category: Hematology Authors: Bart L. Scott, Marcelo C. Pasquini, Mingwei Fei, Raphael Fraser, Juan Wu, Steve M. Devine, David L. Porter, Richard T. Maziarz, Erica Warlick, Hugo F. Fernandez, Robert J. Soiffer, Edwin Alyea, Mehdi Hamadani, Asad Bashey, Sergio Giralt, Nancy L. Geller, Source Type: research